The 340B Rebate Pilot Runs Through the Prescriber's Pen

What HRSA's January start means for physicians and every covered entity type on the Gulf Coast.

On August 3, HRSA published notice that the 340B Rebate Model Pilot Program will proceed. Manufacturer participation plans are due August 24. HRSA approves or rejects them by September 24. The pilot begins January 1, 2027, and HRSA owes Congress an evaluation by April 30, 2028.

Most of the commentary since has been a rerun of the same argument between hospital associations and manufacturers, conducted at the same volume as last year. That argument is not very useful to the people who will actually operate under this program. The pilot touches 25 drugs, and every one of them is an outpatient product prescribed by an ambulatory physician. Whatever this program does, it does through a prescription and a progress note.

Set the trade-association fight aside and three narrower questions come into view. Why did HRSA pick these particular drugs? Which of the fourteen covered entity types actually feel it? And what does it change for the physician writing the script?

Start with why these 25 drugs

The pilot covers products selected under the Medicare Drug Price Negotiation Program for 2026 and 2027. It is tempting to read that as a proxy for high spending, but the better explanation is a statutory collision that has been sitting unresolved since the Inflation Reduction Act passed.

The IRA requires manufacturers to give covered entities the lesser of the 340B ceiling price or the Medicare maximum fair price, and it prohibits stacking the two. Reasonable enough on paper. The difficulty is operational: at the moment a unit leaves the wholesaler, nobody can tell which discount will eventually apply, because that depends on who the drug is dispensed to and how the claim adjudicates. In contract pharmacy arrangements, 340B eligibility is determined retrospectively by definition. CMS built the Medicare Transaction Facilitator to move MFP data around, then stated plainly that it “is not charged with verifying or otherwise reviewing whether a particular drug claim is a 340B-eligible claim.”

That leaves a genuine gap. Two federal discount programs are required not to overlap, and neither agency's plumbing can tell at point of sale whether they are overlapping. Retrospective adjudication is one coherent answer to that problem, and it is the answer manufacturers proposed first. HRSA rejected it in 2024, litigation followed, and the agency has now adopted a narrow version of it under conditions of its own choosing.

This matters for how you argue about the pilot. The drug list is not arbitrary and it is not a stalking horse. It is precisely the set of products where the nonduplication problem actually exists. An argument that treats the rebate model as bad faith will not land with the people writing the legislation, several of whom understand the MFP collision better than the advocacy on either side suggests.

The conditions HRSA attached are also real. Manufacturers pay for the IT platforms. They may not demand purchasing records, encounter-level clinical documentation, or patient information beyond standardized claims elements. Entities keep existing ordering channels. HRSA reserved authority to remove a manufacturer that does not perform. Compared to the design a federal court enjoined in December 2025 and vacated in February, this is a more disciplined program.

What HRSA did not solve is the distribution of the burden, and that is where the analysis should live.

The mechanism change, stated plainly

For thirty-three years the discount arrived at purchase. An entity bought a drug and paid the ceiling price on the invoice. The savings were embedded before anything else happened. Under the pilot, the entity buys closer to list, dispenses, assembles claims data, submits through the manufacturer's platform, and receives a rebate. HRSA set the windows: 45 days after dispensing for the entity to submit, 10 days after a complete submission for the manufacturer to pay.

The price does not change. What changes is when the money arrives and what has to happen in between.

Two consequences follow, and neither requires assuming anyone is acting in bad faith. First, the cash conversion cycle lengthens. Add days in inventory to the 45-day submission window to the 10-day payment window, and set that against wholesaler terms that typically run 30 days or less. An entity is carrying the spread between acquisition cost and ceiling price on a revolving basis. For older brand drugs that have taken repeated price increases, the inflation penalty in the Medicaid rebate formula pushes the ceiling price well below list, which means the spread being carried is largest on exactly the products where 340B does the most work.

Second, a submission deadline now exists where none did before. Under the discount model there was no filing to miss. Under the rebate model a claim not submitted within 45 days is not a late rebate. It is no rebate.

Neither of these is an argument that the model is illegitimate. They are the operating facts, and they fall very unevenly across the program.

Not every covered entity is in this

There are fourteen categories of 340B covered entity, and the commentary tends to collapse them into “hospitals.” The pilot's drug list makes that collapse untenable, because the list determines exposure and the list is a chronic disease formulary. Several entity types are largely outside it in year one.

There are no HIV antiretrovirals among the 25, so Ryan White Parts A, B, C, and D and the AIDS Drug Assistance Programs have limited direct exposure. No factor products, so comprehensive hemophilia treatment centers are insulated. Title X family planning clinics, STD clinics, TB clinics, and Black Lung clinics dispense almost nothing on the list. Children's hospitals catch some overlap through Stelara and Enbrel in pediatric rheumatology and gastroenterology, but their formularies skew away from adult chronic disease. The exposure concentrates elsewhere.

Health centers and look-alikes have the highest exposure per dollar of any entity type, because an FQHC panel is diabetes, hypertension, and COPD, and that is most of the list. Critical access hospitals, sole community hospitals, and rural referral centers carry it through their outpatient and provider-based clinics. Free-standing cancer hospitals face five oncology products at high unit cost. Tribal health programs and urban Indian health centers serve populations with diabetes prevalence well above national rates, which puts them in the same position as health centers. Disproportionate share hospitals have the largest absolute dollar exposure and, generally, the most staff and credit capacity to manage it. A 200-bed DSH hospital has a pharmacy director, a 340B compliance analyst, a treasury function, and a bank and may weather the change without major adjustment. A three-site health center in the Delta has a part-time consultant and a line of credit sized for payroll. Both are covered entities. Only one of them can possibly absorb a 60-day timing change without changing what it stocks.

What changes for physicians

Sort the pilot list by who writes it and the picture sharpens. Seven products are primary care and endocrinology: Januvia, Janumet, Jardiance, Farxiga, Tradjenta, NovoLog, and the semaglutide family of Ozempic, Rybelsus, and Wegovy. Three are cardiology: Eliquis, Xarelto, Entresto. Five are oncology and hematology: Imbruvica, Calquence, Ibrance, Pomalyst, Xtandi. Three are pulmonology: Trelegy Ellipta, Breo Ellipta, Ofev. Three sit across rheumatology, dermatology, and gastroenterology: Enbrel, Stelara, Otezla. Two more are gastroenterology: Linzess and Xifaxan. Two are neurology and psychiatry: Austedo and Vraylar.

There is no inpatient product on the list and no specialty that escapes it. This is an ambulatory prescriber program wearing a pricing program's clothes.

The practical change for physicians employed by or contracting with covered entities is that documentation moves from a compliance obligation to a payment trigger. Under the discount model, the note mattered if HRSA or a manufacturer audited, which was rare and retrospective. Under the rebate model, the claim has to be assembled and filed within 45 days, and it has to tie to an eligible patient encounter. An unclosed chart is now a cash flow variable. Physicians should expect pharmacy and compliance colleagues to start asking for faster note closure and cleaner encounter records, and should understand that the request is not bureaucratic fussiness. That pressure will increase regardless of what happens to the pilot, because both reform bills now moving would write a patient definition into statute requiring a documented provider-patient relationship and an outpatient encounter within the previous 24 months. HRSA's current patient definition has been unsettled since litigation weakened it. Whatever replaces it, the physician's record becomes the eligibility test.

Two other physician-facing effects deserve mention. Formulary behavior may shift, because a pharmacy committee weighing whether to stock a pilot drug now weighs a financing question alongside a clinical one, and the honest answer in some small entities will be to stock less or move patients toward alternatives. And independent physicians who are not part of a covered entity have their own stake here that does not match the hospital position at all. In oncology and rheumatology, where buy-and-bill economics put independent practices in direct competition with 340B-enabled hospital outpatient departments, the pilot narrows that gap on the listed drugs. The Community Oncology Alliance's support for the House reform bill reflects a set of interests that is neither the manufacturers' nor the hospitals'.

The regional overlay

HRSA calculates that the pilot drugs represented less than 5.5 percent of 340B sales in 2025, leaving 94.5 percent under the existing discount model. That is a correct national figure and a weighted average, which means it describes no particular entity. Exposure is a function of patient panel. Thirteen of the twenty-five products treat diabetes, cardiovascular disease, or chronic respiratory disease. Louisiana, Mississippi, Alabama, and Arkansas sit at or near the top of national rankings in all three categories, and Chartis found rural populations in Louisiana, Mississippi, and Arkansas carry the highest diabetes prevalence in the country. A covered entity serving that panel will find a larger share of its 340B purchasing inside the pilot than the national average implies. This is arithmetic, not grievance, and it is the specific fact our delegations should be given.

One entity type has already done this

One 340B entity type has run a rebate model for years. State ADAPs may elect the rebate option, under which the program reimburses retail pharmacies at point of sale and then invoices manufacturers for the discount based on units dispensed, instead of purchasing directly at the 340B price. That experience is the closest thing to evidence anyone has. It shows the model can function at scale. It also shows what it requires: appropriated or borrowed funds sufficient to cover the interval, claims infrastructure capable of accurate unit-level invoicing, and staff who can chase a disputed invoice. Programs that had those things managed. Programs that did not had to build them first. The lesson is not that the rebate model fails. It is that the model works for entities with working capital and claims capacity, and the pilot as designed places no floor under entities that have neither. That is a fixable problem.

The state law gap

Three of the four states have 340B statutes. Arkansas Act 1103 bars manufacturers from denying 340B pricing based on contract pharmacy use, upheld by the Eighth Circuit with certiorari denied in 2024. Mississippi's House Bill 728 of 2024 prohibits discrimination against covered entities and their contract pharmacies and was upheld by the Fifth Circuit. Louisiana's Act 358 of 2023 addresses payor discrimination. Alabama has no comparable statute.

All three were drafted against a discount model. They answer whether the 340B price must be honored. None addresses when a rebate must be remitted, how a denied claim is appealed, or what recourse exists if a submission sits. Alabama entities have no state backstop at all, and the other three have statutes whose application to rebate timing is untested. All four legislatures convene in the first half of 2027, concurrent with the pilot's first quarter. Prompt remittance language, a state-level appeal path, and a timeliness reporting requirement would fit inside frameworks already enacted, and none of them requires taking a position on whether the rebate model should exist.

Where Congress actually is

Two proposals now sit in front of Congress and they do not agree. Senator Bill Cassidy, chairing Senate HELP, released a discussion draft on June 25 that would let manufacturers deliver 340B pricing through upfront discounts, rebates, or an HHS-administered claims repository. It would also cap disproportionate share hospitals, cancer hospitals, and rural referral centers at five contract pharmacy arrangements, generally within the entity's service area.

On July 6, Representatives John Joyce and Scott Peters introduced the SECURE 340B Act, joined by Reps. Auchincloss, Crenshaw, and Barragán. It pauses manufacturer rebate models for four years while an independent clearinghouse is built to validate claims and prevent duplicate discounts, sets contract pharmacy standards without numerical caps, and writes a patient definition into statute. Peters described it as legislation that “closes the loopholes that have allowed the program to drift from its mission, stops the legal chaos that plagues the program today.” It has backing from the National Association of Community Health Centers, the Community Oncology Alliance, and Boston Medical Center Health System.

Between now and January

Plan for the pilot to start. The court that vacated the 2025 version faulted HRSA for treating comment as optional; the agency took 2,475 comments this cycle and wrote systematic responses to the major themes. Hospital groups dispute the record's integrity, pointing to an analysis identifying 1,170 substantially identical submissions. That may matter in litigation. It is not a basis for operational planning.

Read the approved plans in late September rather than waiting for January. Each manufacturer files its own and the terms will differ. The plan is effectively the contract. Model the interval, not the annual administrative estimate. HRSA put the latter at roughly $34,320 per entity and the AHA says that is far too low, but for most entities the binding number is the working capital requirement: days from purchase to dispense, plus 55, times the spread, times volume. Take that number to the wholesaler and the lender in the third quarter.

Fix note closure before you fix anything else. The 45-day window is the constraint that will actually bite, and it depends on clinical documentation that today has no deadline attached to it. Entities should know their current median time to close an encounter, and most do not. Document every denial, partial payment, and delay starting January 1. The HRSA evaluation is due April 30, 2028 and will be built from the 2027 record. That record will be written by whoever keeps it.

The rebate model answers a real problem in federal drug pricing law, and it answers it in a way that shifts a financing burden onto the entities least equipped to carry it and a documentation burden onto physicians who were not consulted about either. Both of those things can be true. The useful work over the next five months is not relitigating whether the pilot should exist. It is making sure that when HRSA writes its evaluation, the record contains what happened in a health center in Monroe and a rural clinic in Meridian, rather than a national average.

Seersucker Strategies advises healthcare, energy, and technology clients on legislative strategy, regulatory affairs, and association management from Louisiana. If your practice or organization is assessing exposure to the 340B rebate pilot, we can help you quantify it and make the case.